反応式
[F:1][C:2]1[CH:7]=[C:6]([S:8]([CH3:11])(=[O:10])=[O:9])[CH:5]=[CH:4][C:3]=1[N:12]1[C:16]2=[N:17][CH:18]=[N:19][C:20]([O:21][CH:22]3[CH2:27][CH2:26][NH:25][CH2:24][CH2:23]3)=[C:15]2[CH:14]=[N:13]1.C([O-])([O-])=O.[K+].[K+].Br[CH2:35][C:36]([C:38]1[CH:43]=[CH:42][C:41]([O:44][C:45]([F:48])([F:47])[F:46])=[CH:40][CH:39]=1)=[O:37]>CN(C=O)C>[F:1][C:2]1[CH:7]=[C:6]([S:8]([CH3:11])(=[O:9])=[O:10])[CH:5]=[CH:4][C:3]=1[N:12]1[C:16]2=[N:17][CH:18]=[N:19][C:20]([O:21][CH:22]3[CH2:23][CH2:24][N:25]([CH2:35][C:36]([C:38]4[CH:39]=[CH:40][C:41]([O:44][C:45]([F:46])([F:47])[F:48])=[CH:42][CH:43]=4)=[O:37])[CH2:26][CH2:27]3)=[C:15]2[CH:14]=[N:13]1参加物
反応物 3
生成物 1
試薬・触媒・溶媒 1
実験手順
In a 10 mL round-bottomed flask fitted with a N2 inlet was placed a stir bar, 1-(2-fluoro-4-methanesulfonyl-phenyl)-4-(piperidin-4-yloxy)-1H-pyrazolo[3,4-d]pyrimidine (43 mg, 0.1 mmol), K2CO3. (138 mg, 1 mmol) and DMF (1 mL). 2-Bromo-1-(4-trifluoromethoxy-phenyl)-ethanone (30 mg, 0.1 mmol) was added in one portion. The reaction mixture was stirred at room temperature for 30 minutes. The resulting suspension was filtered and concentrated under vacuum. The crude was purified by preparative HPLC to give Compound A94. 1H NMR (CDCl3, 400MHz) δ 2.43 (m, 2H), 2.59 (m, 2H), 3.14 (s, 3H), 3.68 (m, 2H), 3.78 (m, 2H), 4.78 (s, 2H), 5.81 (m, 1H), 7.35 (d, 2H), 7.96 (m, 3H), 8.01 (m, 2H), 8.42 (s, 1H), 8.65 (s, 1H). Exact mass calculated for C26H23F4N5O5S 593.14, found 594.3 (MH+).
後処理
- customIn a 10 mL round-bottomed flask fitted with a N2 inlet
- filtrationThe resulting suspension was filtered
- concentrationconcentrated under vacuum
- customThe crude was purified by preparative HPLC
- customto give Compound A94
出典と根拠
- ORDレコード
- ord-b2663d012d4c4d8da1b1160d5d19f92a
- 出典データセット
- uspto-grants-2009_12
- 特許番号
- US07625906B2
関連ノート
読み込み中…